Nanomix develops point-of-care diagnostic tests and a mobile diagnostic platform that can perform multiple in‑vitro assays simultaneously from a single whole‑blood sample. Led by President and CEO David Ludvigson, the company focuses on earlier and more accurate testing in hospital and pre-hospital settings. It is developing initial assays for its platform and plans clinical trial registration and a commercial launch. The company is based in Emeryville, California. Nanomix intends to use the recent financing to advance product development, complete clinical trial registration, and support commercialization of its mobile diagnostic platform and assays.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2014